Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
Krupashankar DS, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy TK, Shah R, Gopal MG, Narayana Rao T, Srinivas CR, Bhat R, Shetty N, Manmohan G, Sai Krishna K, Padmaja D, Pratap DV, Garg V, Gupta S, Pandey N, Khopkar U, Montero E, Ramakrishnan MS, Nair P, Ganapathi PC.
Krupashankar DS, et al. Among authors: narayana rao t.
J Am Acad Dermatol. 2014 Sep;71(3):484-92. doi: 10.1016/j.jaad.2014.01.897. Epub 2014 Apr 2.
J Am Acad Dermatol. 2014.
PMID: 24703722
Clinical Trial.